News

Health Canada has approved Uplizna (inebilizumab-cdon) to treat adults in the country with neuromyelitis optica spectrum disorder (NMOSD) who test positive for disease-driving anti-aquaporin-4 (AQP4) antibodies. The decision adds Canada to the list of nations where the medication is now available. The intravenous or into-the-vein infusion, developed by…

SAB Biotherapeutics has developed therapeutic antibodies — without the need for human donors — that can neutralize self-reactive antibodies associated with autoimmune diseases, such as neuromyelitis optica spectrum disorder (NMOSD). Working in collaboration with CSL Behring, a partnership established in 2020, SAB used its DiversitAb…

Certain long non-coding RNAs (lncRNAs) — a family of molecules that can regulate gene activity — tied to immune function were at significantly higher levels in the blood of people with neuromyelitis optica spectrum disorder (NMOSD) compared with the general population, a study reports. All four evaluated markers —…

Nearly all neuroimmunologists treating patients with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-AQP4 antibodies have prescribed one of the three currently approved therapies: Soliris (eculizumab), Uplizna (inebilizumab-cdon), and Enspryng (satralizumab-mwge). These are the findings of a U.S. survey that also found most responding…

People with neuromyelitis optica spectrum disorder (NMOSD) who switch between treatments more than once because of side effects or non-medical reasons have an increased risk of disease activity, a study shows. While each additional switch for either reason increased the risk of NMOSD activity, no such association was seen…

About 1 in 10 people who are hospitalized for neuromyelitis optica spectrum disorder (NMOSD) are readmitted to the hospital within 30 days, or about one month after discharge, a U.S. study found. Older patients — specifically those in the age range of 65 to 74 — and individuals who…

As many as half of people with neuromyelitis optica spectrum disorder (NMOSD) experience depression, anxiety, and/or sleep problems, according to a new meta-analysis of published studies. Moreover, these symptoms were more frequent among NMOSD patients than in the general population. “There is a high prevalence of depression, anxiety, and…

Blood levels of prolactin, a hormone mostly known for its role in milk production, are significantly elevated in people with neuromyelitis optica spectrum disorder (NMOSD) as compared with healthy adults, a study found. Among NMOSD patients, these high prolactin levels were significantly associated with active disease, sensory-related symptoms, and…

Ultomiris (ravulizumab) is now approved in Canada to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). According to a press release from Alexion Canada, which will market Ultomiris in the country, it’s the “first and only” long-acting therapy…

Uplizna (inebilizumab) prevented disease attacks for people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether they had a genetic variant in the FCGR3A gene that’s associated with reduced efficacy of rituximab, a therapy commonly used off-label for NMOSD. That’s according to additional data analyses from the Phase…